balanc growth balanc sheet
water result confirm concern around weaker growth
compani top line miss driven soft result view
import area unlik earn earlier weak
widespread addit flat instrument growth quarter chemistri
deliv growth lowest growth least year chemistri face
difficult comparison growth modest result make us
increment cautiou sustain histor consist growth
driver beyond weaker-than-expect result driven three
primari issu softer demand biopharma client europ time issu
affect ta instrument revenu modest growth india driven
gst implement weaker rupe believ issu like
compound recent difficulti mass spec compani cede market
share miss innov cycl high resolut portion market
good news manag respond weak look
aggress re-deploy capit optim compani capit structur given
access compani intern cash repatri intend
aggress repurchas share pursu complementari specif water
announc buy-back share target leverag
ratio net debt ebitda end vs net cash
compani also announc host analyst day februari
outlin strategi drive innov re-deploy capit encourag
compani acceler plan deploy capit ultim believ
improv organ growth profil critic water earn higher valuat
current ev/ebitda reiter equal weight rate
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
equal weight admir track
record above-market revenu growth margin
given compani market domin
pharmaceut custom chromatographi
said balanc water success view
difficult gener sustain above-
market earn growth reflect
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
biopharma remain area strength higher
consum margin drive upsid
ebitda expect upsid ebitda
million yield upsid case
fund biotech pressur capit invest
life scienc tool drive downsid
ebitda estim downsid ebitda
million yield downsid case
water result confirm concern around weaker growth
compani top line miss driven soft result view
import area unlik earn earlier weak
widespread addit flat instrument growth quarter chemistri deliv
growth lowest growth least year chemistri face difficult
comparison growth modest result make us increment
cautiou sustain histor consist growth driver beyond
weaker-than-expect result driven three primari issu softer
demand biopharma client europ time issu affect ta instrument
revenu modest growth india driven gst implement
weaker rupe believ issu like compound recent difficulti mass spec
compani cede market share miss innov cycl high
resolut portion market
good news manag respond weak look
aggress re-deploy capit optim compani capit structur given access
compani intern cash repatri intend aggress
repurchas share pursu complementari specif announc
buy-back share target leverag ratio net debt
ebitda end vs net cash compani also announc
host analyst day februari outlin strategi drive
innov re-deploy capit encourag compani
acceler plan deploy capit ultim believ improv organ
growth profil critic water earn higher valuat current
ev/ebitda reiter equal weight rate
lower price target given increas caution around end
market dynam europ india driven recent weak
million prior price target repres prior adjust
ebitda forecast million
lower organ growth guidanc previous
modestli lower ep forecast midpoint
revenu compani forecast organ growth
fx tailwind lead total revenu growth
gross margin expect rang midpoint
would impli y/i declin net interest expens expect approxim
million repres declin previou guidanc million
water also announc new billion expand repurchas plan expand
earn guidanc assum share count million increment
million billion total share buyback expect tax
water anticip non-gaap tax rate repres increas
midpoint lower tax rate benefit expect off-set high
foreign tax headwind modest benefit tax stock-bas
compens account benefit valu corpor tax rate
instead guidanc call ep rang repres
growth y/i foreign exchang expect neutral ep line
guidanc
guid toward organ revenu growth headwind
fx impli total revenu growth guid ep
rang fx expect headwind ep
revenu million expect million
constant currenc growth lower expect model
midpoint manag guidanc revenu repres growth
y/i ex-fx total growth fx headwind compar compani
guidanc million embed organ growth fx
tailwind underli growth across product segment soft quarter
instrument flat y/i ex-fx recur revenu grew y/i ex-fx includ
growth servic chemistri lowest level chemistri growth
least year water attribut weaker result number specif
given uncertainti european region saw softer demand
biopharma custom beyond difficult comp western europ
note uncertainti turkey could impact demand
due time relat issu revenu ta instrument divis fell short
expect quarter weak broad geograph includ
 europ china said compani saw strong order increas
manag convict simpli time issu given ship
product divis directli china possibl trade relat issu
could impact time order
growth india modest quarter driven gst implement
impact countri economi addit note weaker
rupe could impact demand compani mention custom india
tend deliber purchas decis demand unlik rebound
lastli saw weak clinic busi though account
roughli revenu given chang reimburs dynam prescript drug
monitor compani seen softer demand clinic lc/m
continu believ tax reform net posit access
oversea cash billion signific amount alreadi repatri
outweigh neg impact compani non-gaap tax rate specif
water announc billion expans share repurchas program earn
remind compani capit deploy prioriti includ invest
intern busi optim compani balanc sheet return capit
sharehold compani quickli made progress deploy capit toward
prioriti
intern invest compani announc million invest
precis chemistri facil massachusett invest expect
spread next five year includ million capit expenditur
term return capit sharehold announc updat capit
deploy framework earn target net debt-to-ttm
ebitda ratio believ give compani opportun share
repurchas beyond billion commit earn water
repurchas share water embed billion million
repurchas guidanc includ million
 acquir prosolia desi technolog juli million
revenueorgan growth adj day barclay corp
oversea
access oversea cash posit anticip tax reform
neg impact tax rate adjust tax rate
reduct corpor tax rate expect benefit
compani non-gaap tax rate benefit expect off-set increas
tax neg impact tax rate compani foreign incom result
intang base broaden provis lower corpor tax rate
compani also realiz modest benefit stock-bas compens
account tax anticip tax rate rang
repres increas y/i compani expect off-set ep
headwind tax share repurchas result guid weight
share outstand million year
end market perspect biopharma full-year sale result
surprisingli moder ex-fx growth manag comp
lower forecast saw encourag trend market
weak europ india drove soft addit clinic market weaker
due prescript drug monitor reimburs chang industri full-year
sale end market grew ex-fx y/i deceler
manag comp ta grew ex-fx within impli legaci water industri
perform better averag final academ full-year sale end market
grew ex-fx y/i compar organ growth much
challeng quarterli comp water note weak biomed
research demand off-set strength environment research
pharmaceut discoveri remind segment volatil
good read-through coverag given greater instrument exposur
govern exposur within custom class
total thousandscash oversea total oversea barclay corp
growth across geograph end market mix asia drove result
growth y/i ex-fx america increas y/i ex-fx europ
declin ex-fx asia growth driven china y/i growth
india modest europ weak driven soft demand european
pharma clinic biomed research custom partial off-set strength
industri america canada latin america strong flat
water encourag biopharma improv note
off-set clinic ta weak
water geograph divers rev
water revenu breakdown end market
post weaker-than-expect quarter biopharma organ
growth forecast compani saw improv
 larg biopharma custom weaker trend quarter driven weak
europ modest growth india importantli china remain area strength
biopharma driven reimburs dynam prescript drug monitor
clinic busi also weak quarter confer call ceo
chri oconnel note third quarter sale broadli defin pharmaceut categori
increas year-over-year driven double-digit growth
aforement pickup partial off-set modest declin european pharma
market declin sale clinic applic importantli lc product line
remain solid outsid market-rel pocket weak india europ feel
good pharma market posit particular abil meet need
custom biomolecul applic invest biom remain posit
see long-term growth opportun base global pipelin new drug develop
sale custom continu perform well confid posit
larg molecul applic account approxim pharma busi
china
tool average includ agil thermo fisher
academ govern busi grew y/i organ quarter
strength environment research drug discoveri applic demand
biomed research weak second consecut quarter quarterli strength
segment help off-set weaker expect trend biopharma end market
driven healthi academ trend asia america partial off-set
softer trend europ
import rememb academ govern segment
lumpi gener great read-through peer factor point
compar academic/govern exposur peer
mix academic/govern exposur broader mani
peer compani nih busi also dod fbi usda
name gener nih repres academ govern revenu
remaind coverag
academ govern smallest custom class repres
total revenu gener academic/govern custom major util
chromatographi system also mean percentag revenu
consum servic stream lower area instead sale gener
driven high-end mass spectrometri placement lumpi quarterli
basi chromatographi largest product segment monitor
biopharma trend better read segment perform addit
natur market academ govern notabl sticki
trend tend vari per quarter
similarli less consum revenu academic/govern
custom class peer water broad consum stream lab
suppli sampl prep like thermo fisher agil drive consist
govern academ exposur
end market perform quarter
revenu grew organ ta instrument
water divis revenu growth ex-fx y/i water divis
revenu million came million expect
million increas y/i organ basi revenu increas y/i
estim chemistri revenu miss organ expect
versu expect organ instrument revenu
expect growth currenc headwind segment
revenu quarter versu forecast management guidanc
ta instrument divis revenu growth ex-fx y/i ta instrument
revenu million came million estim increas
organ y/i versu forecast organ currenc neutral
quarter versu estim headwind
market y/i y/i growth y/i y/i growth y/i y/i growth y/i growth barclay corp
water revenu segment million
non-gaap ep increas y/i buoy better oper margin
lower interest expens lower share count partial off-set higher tax rate
note ep came toward high end manag guidanc
despit compani non-gaap tax rate expect
compani mid-point guidanc compani share count
came expect ad ep rel model
adjust ep came modestli estim consensu
water non-gaap ep growth
gross margin came expect believ delta
rel expect could driven mix given instrument growth
weaker quarter gross margin flat y/i full year
compani continu expect gross margin flat y/i
despit lower revenu ep guidanc
water gross margin adjust ebitda
sg ex-stock comp expens y/i revenu
 expens total revenu y/i model
rel steadi expenditur compani continu invest intern growth
water adjust sg trend
adjust oper incom million grew y/i came line
estim oper margin y/i
estim better-than-expect gross margin lower-than-expect
total sg includ stock comp partial off-set higher
spend revenu higher
water ebit margin annual growth
deliv million cffo modestli forecast
minor delta larg driven work capit vs
model compani activ share repurchas repurchas
share model quarterli compani end
roughli author remain buy-back ad
addit billion author result tax reform
compani increas access oversea cash believ could result
acceler capit deploy activ pleas see observ two detail
water use oper million
 mm except ep reportedincom growth profit ebitda ebit debt pre-tax pre-tax tax net net researchprior yearprior quarter barclay corp
estestestestestestestestestincom statement growth growth growth growth growth growth y/i growth y/i organ adj growth product product product revenu inc product revenu inc servic servic gross gross margin inc gross margin inc growth growth y/i administr growth growth y/i base sg stock base oper growth growth y/i ebitda growth acquir intang oper incom ebit growth debt invest pre-tax pre-tax growth benefit incom tax net net growth adj adj barclay corp
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
